Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2025 10:00 ET | Source: Replimune Group Inc - RP1…
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025 16:01 ET | Source: Replimune Group Inc WOBURN, Mass.,…
Replimune Announces Inducement Grants Under NasdaqListing Rule 5635(c)(4)
February 07, 2025 16:01 ET | Source: Replimune Group Inc WOBURN, Mass.,…
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation…